Abstract
Three different approaches were employed to assess various markers associated with sex differences in responses to methamphetamine (MA). Bioassay measures reveal that MA treatment results in significantly greater reductions in body weight and increases in body temperature in male mice. Protein and mRNA determinations show significant increases in Bcl-2 and PAI-1 in male mice, while females show significant increases in GFAP and decreases in IGF-1R following treatment with MA. In mice with a heterozygous mutation of their dopamine transporter (+/- DAT), only female mice show significant differences in dopamine transporter binding and mRNA and associated reductions in striatal dopamine content along with increases in MA-evoked striatal dopamine output. The identification of these sex-dependent differences in markers provides a foundation for more exhaustive evaluation of their impact upon, and treatment of, disorders/neurotoxicity of the nigrostriatal dopaminergic system and the bases for the differences that exist between females and males.
Keywords: Body Weight, Body Temperature, GFAP, Bcl-2 PAI-1, IGF-1R, Dopamine Transporter, Body Weight, Body Temprature, Bcl-2 PAI, IGF-IR, Methamphetamine (MA), dihyroxyphenylacetic acid (DOPAC), Neurotoxicity, PAKT, GSK3 B, mRNA
Current Neuropharmacology
Title: Markers Associated with Sex Differences in Methamphetamine-Induced Striatal Dopamine Neurotoxicity
Volume: 9 Issue: 1
Author(s): D. E. Dluzen, J. L. McDermott, M. Bourque, T. Di Paolo, A. S. Darvesh, A. B. Buletko and N. J. Laping
Affiliation:
Keywords: Body Weight, Body Temperature, GFAP, Bcl-2 PAI-1, IGF-1R, Dopamine Transporter, Body Weight, Body Temprature, Bcl-2 PAI, IGF-IR, Methamphetamine (MA), dihyroxyphenylacetic acid (DOPAC), Neurotoxicity, PAKT, GSK3 B, mRNA
Abstract: Three different approaches were employed to assess various markers associated with sex differences in responses to methamphetamine (MA). Bioassay measures reveal that MA treatment results in significantly greater reductions in body weight and increases in body temperature in male mice. Protein and mRNA determinations show significant increases in Bcl-2 and PAI-1 in male mice, while females show significant increases in GFAP and decreases in IGF-1R following treatment with MA. In mice with a heterozygous mutation of their dopamine transporter (+/- DAT), only female mice show significant differences in dopamine transporter binding and mRNA and associated reductions in striatal dopamine content along with increases in MA-evoked striatal dopamine output. The identification of these sex-dependent differences in markers provides a foundation for more exhaustive evaluation of their impact upon, and treatment of, disorders/neurotoxicity of the nigrostriatal dopaminergic system and the bases for the differences that exist between females and males.
Export Options
About this article
Cite this article as:
E. Dluzen D., L. McDermott J., Bourque M., Di Paolo T., S. Darvesh A., B. Buletko A. and J. Laping N., Markers Associated with Sex Differences in Methamphetamine-Induced Striatal Dopamine Neurotoxicity, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795017399
DOI https://dx.doi.org/10.2174/157015911795017399 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Inflammatory Effects of Triterpenoids; Naturally Occurring and Synthetic Agents
Mini-Reviews in Organic Chemistry Genetic and Non-genetic Determinants of Cardiovascular Disease in South Asians
Current Diabetes Reviews A Multi-layered Particulate System for Desvenlafaxine Succinate Oral Customized Release
Current Drug Delivery Magnetic Resonance Imaging in Alzheimer’s Disease: from Diagnosis to Monitoring Treatment Effect
Current Alzheimer Research Editorial [Hot Topic: Cannabinoid Receptors Ligands (Guest Editor: Gabriele Murineddu)]
Recent Patents on CNS Drug Discovery (Discontinued) Recent Applications of Doebner, Doebner-von Miller and Knoevenagel-Doebner Reactions in Organic Syntheses
Current Organic Synthesis RNA as a Drug Target: Recent Patents on the Catalytic Activity of Trans- Splicing Ribozymes Derived from Group I Intron RNA
Recent Patents on DNA & Gene Sequences Parkinsons Disease and Obsessive-Compulsive Phenomena: A Systematic Review
Current Psychiatry Reviews Computer Aided Drug Design and its Application to the Development of Potential Drugs for Neurodegenerative Disorders
Current Neuropharmacology Effectiveness of Hsp90 Inhibitors as Anti-Cancer Drugs
Mini-Reviews in Medicinal Chemistry Steroid 5α-Reductase as a Novel Therapeutic Target for Schizophrenia and Other Neuropsychiatric Disorders
Current Pharmaceutical Design Multi-Target Directed Drugs as a Modern Approach for Drug Design Towards Alzheimer’s Disease: An Update
Current Medicinal Chemistry Inhibition of GSK3 Dependent Tau Phosphorylation by Metals
Current Alzheimer Research Severe Asthma: Why do Some Children Not Respond to Treatment?
Current Pediatric Reviews Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design Editorial (Thematic Issue: Rational Approaches for the Design of Monoamine Oxidase Inhibitors)
Central Nervous System Agents in Medicinal Chemistry The Effects of CCRC on Cognition and Brain Activity in aMCI Patients: A Pilot Placebo Controlled BOLD fMRI Study
Current Alzheimer Research Jun Dimerization Protein 2: A Multifunctional Transcription Factor in Mammalian Cells
Current Genomics Ceftriaxone and Phenylalanine Combination as Broad Spectrum Antimicrobials Therapy
Current Drug Therapy Association between Thiopurines Use and Pregnancy Outcomes in Female Patients with Inflammatory Bowel Disease: A Meta-Analysis
Current Pharmaceutical Design